Mukka Proteins shareholders approve ₹470 crore warrant issue
Mukka Proteins secured shareholder approval for a ₹470 crore preferential issue of warrants at ₹23.50 each. The resolution passed with 99.96% support, with proceeds earmarked for working capital and expansion.

*this image is generated using AI for illustrative purposes only.
Mukka Proteins shareholders have approved the issuance of 2,00,00,000 convertible warrants, aggregating up to ₹470 crore, through a postal ballot. The special resolution was passed with 99.96% of the valid votes cast in favour, deemed approved on July 12, 2026. The approval follows a corrigendum issued on July 06, 2026, which clarified the utilization of proceeds and pricing basis following observations from the National Stock Exchange of India Limited and BSE Limited.
The preferential issue involves the issuance of warrants at a price of ₹23.50 per warrant. The proceeds are proposed to be allocated across working capital requirements, business expansion, and general corporate purposes. The company stated that the allocation provides flexibility to support long-term growth and operational scale.
| Sr. no | Purpose/Object(s) of the Preferential Issue | Estimated amount to be utilized for each of the Objects (Amount in Rs.) | Tentative timeline for utilization of issue proceeds from the date of receipt of funds |
|---|---|---|---|
| 1 | Working Capital Requirements | Rs. 35,00,00,000 | As estimated by management |
| 2 | Funding Business Expansion Plans | Rs. 5,00,00,000 | Entire proceeds utilized within 24 months |
| 3 | General Corporate Purposes | Rs. 7,00,00,000 | |
| Total | Rs. 47,00,00,000/- |
Voting Results
The remote e-voting process commenced on June 13, 2026, and concluded on July 12, 2026. A total of 22,01,79,675 votes were cast in favour of the resolution, while 82,433 votes were cast against it. The scrutinizer's report, dated July 13, 2026, confirmed that no requests were received from members seeking modification of their votes following the corrigendum.
Pricing and Valuation
The issue price of ₹23.50 per warrant was determined based on the higher of the floor price calculated under Regulation 164(1) of the SEBI ICDR Regulations and the fair value determined by an independent registered valuer. The floor price was calculated at ₹23.18 per equity share, derived from the 90-day volume weighted average price (VWAP) on the NSE. The fair value, assessed by Ms. Kavita Joshi, Chartered Accountant and Registered Valuer, was determined at ₹18.14 per share.
Historical Stock Returns for Mukka Proteins
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.25% | -0.85% | -2.82% | +5.68% | -20.77% | -44.47% |
What specific business expansion initiatives will the ₹50 crore allocation target?
How will the conversion of these warrants impact the company's earnings per share in the long term?
What are the expected operational efficiencies or revenue growth resulting from the increased working capital?































